Ocular Therapeutix eyes a $24M Series D extension | Wall Street Beat

January 28, 2013 by MassDevice staff

Ocular Therapeutix raises another $24 million for its punctum plugs to treat eye diseases such as glaucoma.

MassDevice.com Wall Street Beat

Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.

The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.

Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.

Sign up to get our free newsletters delivered straight to your inbox

President & CEO Amar Sawhney told MassDevice.com that the company plans to use the funds to back clinical trials of the device and hopes to then commercialize the technology in the U.S.

"There are many punctum plug-based products. We're focused on glaucoma and post-operative inflammation using a steroid," Sawhney told us. "Generally speaking, we would be doing Phase II trials for both of those indications next year. We would potentially be doing Phase III trials and after that, obviously, [FDA] submission would take place."

Ocular Therapeutix is also awaiting word from the federal watchdog agency on the pre-market approval application for its ReSure sealant, a hydrogel used to protect ocular incisions following eye surgery.

"We're very excited. We expect to have some sort of approval some time later this year," Sawhney said.

Comments